StockData

Cartesian Therapeutics, Inc. (RNAC) company profile

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.08−0.27 (-4.25%)

Close on Nov 16, 2026Market cap $183.95MP/E –Yield –

About Cartesian Therapeutics

Pharmaceutical Preparations, SIC 2834

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company that develops mRNA-engineered cell therapies for the treatment of autoimmune diseases. The company uses a proprietary platform to insert messenger RNA into cells, enabling outpatient administration without the need for pre-treatment chemotherapy or viral integration. Its lead product candidate is Descartes-08, an autologous chimeric antigen receptor T-cell therapy in clinical evaluation for conditions such as generalized myasthenia gravis and myositis. The company also developed Descartes-15 for multiple myeloma and explores in-vivo cell engineering technologies. Its primary target patients are individuals living with serious, chronic autoimmune disorders.

The company is headquartered in Frederick, Maryland, where it operates an internal, current good manufacturing practice compliant facility for research, development, and clinical cell therapy production. Cartesian conducts clinical trials across multiple patient cohorts in the United States. Its intellectual property portfolio includes issued and pending patents across various global jurisdictions, including the United States, Canada, Israel, Japan, and South Korea.

Summary of the business section of Cartesian Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Cartesian Therapeutics, Inc.
Founded
2007
Headquarters
Frederick, MD
Address
7495 New Horizon Way 21703
Phone
(301) 348-8698
Employees
75, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
RNAC
Former tickers
SELB until Nov 27, 2023
Exchange
Nasdaq
IPO date
Jun 23, 2016
Shares outstanding
30M, Jul 31, 2026
Public float
$108.74M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-30 reverse, Apr 5, 2024
SEC CIK
1453687
CUSIP
816212104
ISIN
US8162121045
FIGI
BBG001J19Q25
Share class FIGI
BBG001V0FQQ0
LEI
529900NMN0LACZOL7C43
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Carsten BrunnPresident and CEO, Director323,530
Milos MiljkovicChief Medical Officer58,820
Blaine DavisChief Financial Officer121,220
Emily EnglishChief Operations Officer94,226
June Ann SeymourChief Accounting Officer6,500
Christopher M. JewellChief Scientific Officer62,490
Metin KurtogluChief Technology Officer62,258
Michael SingerDirector544,381
Timothy C. BarabeDirector56,966
Patrick J. ZennerDirector12,974
Nishan M. DeSilvaDirector11,366
Timothy A. SpringerDirector9,633,493
Kemal MalikDirector11,133
Adrian Ion BotDirector5,800
Carrie Smith CoxDirector15,629

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.33M-$633.79K$2.02M$25–
FY2024$7.31M$6.54M$2.79M$61–
FY2023$6.11M$6.38M$1.82M$70–
FY2022$4.29M-$588.62K$1.66M$35–
FY2021$3.67M$4.28M$1.34M$108–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Carsten Brunn
President and Chief Executive Officer
$674.00K$973.48K$2.31M$363.96K$4.11K$4.33M-41%
Blaine Davis
Chief Financial Officer
$475.86K$372.46K$884.12K$205.57K$11.91K$1.95M-51%
Milos Miljkovic
Chief Medical Officer
$439.00K$321.67K$766.42K$118.53K$11.91K$1.66M+23%
Christopher Jewell
Former Chief Scientific Officer
$390.67K$375.05K$661.81K$144.20K$443.98K$2.02M+19%
Metin Kurtoglu
Former Chief Technology Officer
$163.49K$775.93K$984.44K$60.43K$489.74K$2.47M-9%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 23, 2016
Offer price
$14.00
Securities offered
5,000,000
Gross proceeds
$70.00M
Exchange
Nasdaq
Lock-up ends (est.)
Dec 20, 2016

“The initial public offering price per share is $14.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 75 full-time employees, 62 of whom are primarily engaged in research and development activities and 13 of whom are primarily engaged in corporate functions.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 19, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 13, 2023Name changeName changed from SELECTA BIOSCIENCES INC to Cartesian Therapeutics, Inc.
Nov 13, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 14, 2023Late filingNotification of late filing
Jun 3, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 23, 2016IPOInitial public offering priced (424B4 prospectus)
Jun 8, 2016ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?